x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Cancer Letter

The Cancer Letter

The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973. With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology, providing authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. This weekly podcast features interviews,

health & fitness medicine

All Episodes

00:17:47

Roy Herbst remembers the late Edward Chu, “the...

The Cancer Letter ·

2025/12/03

Edward Chu, director of the Montefiore Einstein Comprehensive Cancer Center, died on Nov. 13 from glioblastoma. He was 66.In the most recent issue of The Cancer Letter, Roy S. Herbst, deputy director at Yale Cancer Center, penned an obituary for Chu chronicling the career and impact of the “baritone of reason.” In this week’s episode of The Cancer Letter Podcast, Herbst sat down with Paul Goldberg, editor of The Cancer Letter, and shared stories about meeting Chu on a sailboat in Rhode Island,

en

00:19:09

Oncofertility has been an overlooked standard of...

The Cancer Letter ·

2025/11/26

Recently, a wave of new private insurance mandates have swept the nation making fertility preservation a covered benefit for people with cancer in 21 states plus Washington, DC. Mia Sandino, an osteosarcoma survivor, chose not to undergo fertility preservation when she was diagnosed at 19. She didn’t know if she wanted kids, had no guarantee that her insurance would cover the extraordinary costs, and feared postponing treatment would delay her return to "normal life."This episode is

en

00:29:03

Ellen Sigal and Karen Knudsen “gush” about new CDER...

The Cancer Letter ·

2025/11/19

Last week, Richard Pazdur was named to the position of director of FDA’s Center for Drug Evaluation and Research. Much has been written about how Pazdur, with nearly a three-decade long career at the agency, represents a stabilizing choice for FDA as it faces inner and outer turmoil.Indeed, on this week’s episode of In the Headlines, we bring you the full audio of a conversation originally published in print in last week’s issue of The Cancer Letter between Ellen Sigal, chair and founder of Friends

en

00:33:24

Tidmarsh is out, Pazdur is in: FDA’s CDER under new...

The Cancer Letter ·

2025/11/12

Richard Pazdur, founding director of FDA’s Oncology Center of Excellence and long-time FDA visionary, has accepted the top job at FDA’s Center for Drug Evaluation and Research following George F. Tidmarsh’s dramatic ouster from the position. “This is big. Because, you know, the whole field of oncology over the past 25 years—and [Pazdur has] run the oncology division and decided which drugs would get on the market, which drugs won't get on the market. Everybody is speaking ‘Pazdurese,’” said

en

00:58:57

The Directors: Ruben Mesa and Kunle Odunsi on how...

The Cancer Letter ·

2025/11/07

At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.“I was born in Nigeria, I grew up in Nigeria, I went to medical school in Nigeria, and then I did some of my training in England, in the United Kingdom,” Odunsi said. “My residency in obstetrics and gynecology was at Yale School of Medicine, so it was a very welcoming

en

00:19:38

Site visits are gone, but outlook for new,...

The Cancer Letter ·

2025/11/05

One of the first things that happened as part of President Donald Trump’s “flooding of the zone” in January was the disappearance of the site visit as part of the Cancer Center Support Grant review.In last week’s cover story, Paul Goldberg, editor and publisher of The Cancer Letter, wrote about “the high level of consternation over the disappearance of the site visit from the CCSG review” and how cancer centers are adapting to the new, centralized review process. In this episode of The Cancer Letter

en

00:26:41

Early endpoints are a balance of risk and benefit

The Cancer Letter ·

2025/10/29

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients. “If we don't have these intermediate endpoints to get new drugs to patients, we'd have to wait… I think somebody mentioned in one of the conversations I had while I was reporting on this, that the readout would be upwards of 17 years to get information about these new drugs

en

00:35:00

Cliff Hudis on how AI in cancer care is...

The Cancer Letter ·

2025/10/22

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.On this week’s episode of The Cancer Letter Podcast, Hudis spoke with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb,

en

00:28:19

Latinx oncology leaders talk about the impact of...

The Cancer Letter ·

2025/10/15

In honor of Hispanic Heritage Month, this week’s episode of The Cancer Letter Podcast features three oncology leaders whose research focuses on identifying and solving health disparities specifically in the Latinx community. Ruben A. Mesa, Amelie Ramirez, and Luis Carvajal Carmona spoke about the concrete impact of federal policy stances on cancer outcomes in Latinx patients.Mesa, who is president of the Advocate Health Cancer National Service Line, president of the Atrium Health Levine Cancer, and

en

01:05:54

The Directors: Steven Artandi and Eric Winer on how...

The Cancer Letter ·

2025/10/10

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. “The uncertainty in the current system is giving some people pause, especially younger people, whether they’re Americans or whether they trained abroad, as to whether the United States is the right place to spend their

en

00:27:11

Pulitzer-winning healthcare reporter Laurie McGinley...

The Cancer Letter ·

2025/10/08

“Patient stories, as you know, can either make or break a story,” said Laurie McGinley, a former health and science editor at The Washington Post who is now on the board of Patient Action for Cancer Research, or PACR, a new advocacy organization aimed at organizing and amplifying patient voices in an effort to protect life-saving federal health research.In last week’s issue, The Cancer Letter reporter Sara Willa Ernst wrote about how PACR is building a repository of patient stories to better connect

en

00:22:37

With Anthony Letai’s appointment, NCI is now under...

The Cancer Letter ·

2025/10/01

With little fan fare, Anthony Letai, a highly respected physician-scientist, was sworn in as the 18th director of the National Cancer Institute on Sept. 29. Then, two days later, on Oct. 1, the government shut down.The news of Letai’s apparent appointment was broken last week in the media, with no word from the White House. Although HHS has published a press release announcing Letai’s appointment, the White House is still silent on the matter. Meanwhile, Trump’s FDA initiated an unusual regulatory

en

00:19:15

Congress seems to have NCI’s back—is cautious...

The Cancer Letter ·

2025/09/24

With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.Following firm bipartisan pushback against the White House’s proposed budget cuts for FY2026, both the House and Senate have reaffirmed their support for biomedical research. At last week’s annual symposium marking the 50th anniversary of UNC Lineberger Comprehensive Cancer Center first securing its

en

00:40:10

Jonathan Mahler on his front-page story in the NYT...

The Cancer Letter ·

2025/09/17

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.In this episode

en

00:54:15

The Directors: Ben Ho Park and Suresh Ramalingam on...

The Cancer Letter ·

2025/09/12

In the face of the unknown, two cancer center leaders discuss planning for the future, recovering from their losses, and holding on to what they still have. Right now, there are more questions than answers. “It's hard to plan, and try to make sure that what we're doing in the cancer research space is going to be funded,” said Ben Ho Park, director of the Vanderbilt-Ingram Cancer Center. “What programs, some of which have already been pulled, will not be pulled? Or even if they're cut

en

00:43:32

On Capitol Hill, NIH gets congressional support and...

The Cancer Letter ·

2025/09/10

As NIH and NCI funding is negotiated in Congress, Paul W. Thurman felt compelled to crunch some numbers. He compared the U.S.’s cumulative funding for NCI to the funding slated for ICE—the latter of which vastly outweighs the former—and asked whether the funding priorities of the federal government are properly representing the nation’s mortality. “I think the way a government or the way a people spends its money talks not only about its priorities, but about its morality,” Thurman says in this

en

00:32:22

Robert A. Winn on his new vision to train cancer...

The Cancer Letter ·

2025/09/03

When Robert A. Winn was named director of the University of Illinois Cancer Center in 2015, he knew that the skills required to be a successful cancer center director were very different from the skills he drew upon to be a successful scientist. So, he formed an informal, personal mentorship team.“I know they got tired of me, but I called them almost once a month,” Winn said.In this episode of The Cancer Letter Podcast, Winn spoke with Paul Goldberg, editor and publisher of The Cancer Letter, about

en

00:54:29

Gardiner Harris, acclaimed health care and pharma...

The Cancer Letter ·

2025/08/27

In his new book, “No More Tears: The Dark Secrets of Johnson & Johnson,” Gardiner Harris, who was previously the public health and pharmaceutical business reporter for The New York Times, talks about the history of the overuse of red blood cell growth factors in oncology. In conversation with The Cancer Letter editor and publisher Paul Goldberg, Harris and Goldberg discuss their parallel coverage of ESAs—erythropoiesis-stimulating agents.Harris’s book, released last April, is a New York Times

en

00:17:22

In The Headlines: Brian Druker on receiving a...

The Cancer Letter ·

2025/08/20

Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.The gift—which appears to be the largest single donation ever made to any U.S. university, college or academic health center—was announced together with an organizational restructuring that makes the Knight Cancer Institute into a self-governed entity within Oregon Health and Science University. The move also brings back the OHSU cancer center’s longtime leader and star scientist Brian Druker, who will serve

en

00:26:36

In The Headlines: Late poet Andrea Werblin Reid’s...

The Cancer Letter ·

2025/08/13

In the last three years of her life, Andrea Werblin Reid wrote 150 poems on living with ovarian cancer and end of life. Werblin Reid died of ovarian cancer in 2022. Her third collection of poetry, “To See Yourself As You Vanish,” will be published Sept. 9. In this episode of In the Headlines, Jacquelyn Cobb, associate editor with The Cancer Letter, talks to Werblin Reid’s husband, Angus (Gus) Reid, and Werblin Reid’s friend, Sarah K. Sawyer. The two co-authored a story in last week’s issue of The

en

55 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown